PPT-Percutaneous Closure of the Left Atrial Appendage

versus Warfarin Therapy for Prevention of Stroke in Patients with Atrial Fibrillation A Randomized NonInferiority Trial David R Holmes MD Vivek Y Reddy MD Zoltan G Turi MD Shephal K Doshi MD. The LAA is a normal part of the heart anatomy and causes no problems in the general population However this pouch is a major source of blood clots in patients with atrial fibrillation Atrial fibrillation AF is the biggest risk factor for blood clots The following information about the WATCHMAN implant is important for you to know along with medication recommendations and common questions you may have about your implant UNDERSTANDING YOUR HEART This section will discuss the basic function of th www.watchmandevice.com. AF is a Growing Problem Associated with Greater . Morbidity and . Mortality . ~5 M. people with . AF in U.S., expected to more than double by 2050. 1. AF = most . common cardiac . T. hrombus . at the device, . leakage . at follow-up, . device . embolisation. , . post. -procedural drug regimen and . impact . of center experience . data . from the prospective 1025 patients . EWOLUTION Registry. Mike Clark, M.D.. Figure 18.23. (a) Day 20:. . Endothelial. . tubes begin. . to fuse.. (b) Day 22:. . Heart. . starts. . pumping.. . (c) Day 24: . Heart. . Percutaneous. Left Atrial Appendage (LAA) Exclusion. Aaditya Vora, MD. Cardiac Electrophysiologist. Baptist heart specialists. Disclosures. None. > . 33M. people with . AF Worldwide. 1. Many patients are unprotected. Vivek Y. Reddy MD. 1. *, Douglas N. Gibson MD. 2. , . Saibal. Kar. 3. , William O’Neill MD. 4. , . Shephal. K. . Doshi. MD. 5. , Rodney P. Horton MD. 6. , Maurice . Buchbinder. MD. 7. , Nicole T. Gordon BSEE. Health economic and reimbursement information provided by Boston Scientific Corporation is gathered from third-party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules and policies. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice. Boston Scientific encourages providers to submit accurate and appropriate claims for services. . Product Overview . MKT-2387A-G. LAA Management Guidelines. MKT-2387A-G. Society. Recommendation. STS (2017). “It is REASONABLE to perform left atrial appendage excision or exclusion in conjunction with surgical ablation for AF for longitudinal thromboembolic morbidity prevention. (Class IIA, Level C limited data)” . The Randomized MITHRAS Trial. . Philipp . Lurz. , Matthias . Unterhuber. , Karl-Philipp Rommel, Karl-. Patrik. . Kresoja. , . Tobias . Kister. , Christian Besler, Karl . Fengler. , Marcus Sandri, Ingo . CARDIAC INTERVENTIONS TODAY 29 A trial septal defect (ASD) is the second most com - mon congenital cardiac anomaly. In this article, we review the physiology of ASD, as well as the indications and m A retrospective study of atrial septal defect . IAIM, 2016; 3(10 ): 7 - 16. Page 7 Original Research Article A retrospective study of atrial septal defect G Ravindra 1* , Abhijeet M Dashetwar 1 1 As Seminar Atrial septal defectsTal Geva, Jose D Martins, Rachel M WaldAtrial septal defects are the third most common type of congenital heart disease. Included in this group of pulmonary circulations. JR. GENERAL MEDICINE. Introduction. 6-10% of all cardiac . anomalies. M:F = 1:2 [ sinus . venosus. defects 1:1. ]. 1 in 1500 live . births. Most . common congenital abnormality in adult > 40yrs [30-40.